Omeros Corporation
- Jurisdiction
United States - LEI
549300CJWLXX2MXVVV71 - ISIN
US6821431029 (OMER )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. Read full profile
Fundamentals
- Net revenue
€351.42K - Gross margin
-48.5% - EBIT
-€118.04M - EBIT margin
-33,589.8% - Net income
-€104.46M - Net margin
-29,726.7%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: May 15, 2024 (Q1 2024)